Abstract:Cisplatin, a chemotherapeutic agent, can cause nephrotoxic and ototoxic injuries. Using a mouse model of repeated low dose cisplatin (RLDC), we compared the kidneys of cisplatin- and vehicle-treated mice on days 3 (early injury phase) and 35 (late injury/recovery phase) after the final treatment. RNA-seq analyses revealed increases in the expression of markers of kidney injury (e.g., lipocalin 2 and kidney injury molecule 1) and fibrosis (e.g., collagen 1, fibronectin, and vimentin 1) in RLDC mice. In addition, we observed increased expression of polyamine catabolic enzymes (spermidine/spermine N1-acetyltransferase, Sat1, and spermine oxidase, Smox) and decreased expression of ornithine decarboxylase (Odc1), a rate-limiting enzyme in polyamine synthesis in mice subjected to RLDC. Upon confirmation of the RNA-seq results, we tested the hypothesis that enhanced polyamine catabolism contributes to the onset of renal injury and development of fibrosis. To test our hypothesis, we compared the severity of RLDC-induced renal injury and fibrosis in wildtype (WT), Sat1-KO, and Smox-KO mice. Our results suggest that the ablation of polyamine catabolic enzymes reduces the severity of renal injury and that modulation of the activity of these enzymes may protect against kidney damage and fibrosis caused by cisplatin treatment.

What problem does this paper attempt to address?

The problem this paper attempts to address is the role of polyamine metabolism in cisplatin-induced kidney injury and fibrosis. Specifically, the researchers used a repeated low-dose cisplatin (RLDC) mouse model to simulate the clinical scenario of cancer patients receiving cisplatin treatment. By comparing the kidney changes in the cisplatin-treated group and the control group of mice at the early injury stage (day 3) and the late injury/recovery stage (day 35), the researchers aim to understand the specific roles of key enzymes in the polyamine metabolic pathway (such as SAT1 and SMOX) in the development of kidney injury and fibrosis. The main hypothesis of the study is that enhanced polyamine metabolism leads to exacerbated kidney injury and fibrosis. To test this hypothesis, the researchers compared the extent of kidney injury and fibrosis in wild-type (WT), SAT1 gene knockout (Sat1-KO), and SMOX gene knockout (Smox-KO) mice after RLDC treatment. The results indicate that knocking out polyamine metabolic enzyme genes can reduce the extent of kidney injury, suggesting that regulating the activity of these enzymes may help protect the kidneys from cisplatin-induced injury and fibrosis.

Polyamine Catabolism and Its Role in Renal Injury and Fibrosis in Mice Subjected to Repeated Low-Dose Cisplatin Treatment